



FORM PTO-1449 (Modified) Approved for use through 10/31/2002			US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Bucket No. 50623.26	Application No. 09/748,122	
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)			Applicant Wouter E. Roorda				
			Filing Date December 21, 2000		Group Art Unit 738		
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate
	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	
	A2	4,733,665	3/29/88	Palmaz	128	343	
	A3	4,800,882	1/31/89	Gianturco	128	343	
	A4	4,886,062	12/12/89	Wiktor	128	343	
	A5	4,931,287	6/5/90	Bae et al.	424	484	
	A6	4,977,901	12/18/90	Ofstead	128	772	
	A7	5,171,217	12/15/92	March et al.	604	53	
	A8	5,328,471	7/12/94	Slepian	604	101	
	A9	5,383,928	1/24/95	Scott et al.	623	1	
	A10	5,464,650	11/7/95	Berg et al.	427	2.30	
	A11	5,575,815	11/19/96	Slepian et al.	623	1	
	A12	5,578,073	11/26/96	Haimovich et al.	623	1	
	A13	5,605,696	2/25/97	Eury et al.	424	423	
	A14	5,628,730	5/13/97	Shapland et al.	604	21	
	A15	5,667,767	9/16/97	Greff et al.	424	9.411	
	A16	5,670,558	9/23/97	Onishi et al.	523	112	
	A17	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A18	5,716,981	2/10/98	Hunter et al.	514	449	
	A19	5,780,044	7/14/98	Yewey et al.	424	426	
	A20	5,800,392	9/1/98	Racchini	604	96	
	A21	5,817,343	10/6/98	Burke	424	489	
	A22	5,824,049	10/20/98	Ragheb et al.	623	1	
EXAMINER <u>H - P</u>			DATE CONSIDERED <u>05/31/2004</u>				
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.26	Application No. 09/748,412		
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Applicant Wouter E. Roorda			
				Filing Date December 21, 2000	Group Art Unit 3738		
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
DR	A23	5,830,178	11/3/98	Jones et al.	604	49	
	A24	5,837,008	11/17/98	Berg et al.	623	1	
	A25	5,837,313	11/17/98	Ding et al.	427	2.21	
	A26	5,851,231	12/22/98	Wolff et al.	623	1	
	A27	5,851,508	12/22/98	Greff et al.	424	9.411	
	A28	5,865,814	2/2/99	Tuch	604	265	
	A29	5,869,103	2/9/99	Yeh et al.	424	501	
	A30	5,873,904	2/23/99	Ragheb et al.	623	1	
	A31	5,951,586	9/14/99	Berg et al.	606	198	
	A32	5,971,954	10/26/99	Conway et al.	604	96	
	A33	5,980,928	11/9/99	Terry	424	427	
	A34	5,980,972	11/9/99	Ding	427	2.24	
	A35	5,981,719	11/9/99	Woiszwillio et al.	530	410	
	A36	6,010,530	1/4/00	Goicoechea	623	1	
	A37	6,015,541	1/18/00	Greff et al.	424	1.25	
	A38	6,096,070	8/1/00	Ragheb et al.	623	1	
	A39	6,110,483	8/29/00	Whitbourne et al.	424	423	
	A40	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	A41	6,165,212	12/26/00	Dereume et al.	623	1.13	
	A42	6,214,901	4/10/01	Chudzik et al.	523	113	
	A43	6,262,034	7/17/01	Mathiowitz et al.	514	44	
	A44	6,263,880	7/24/01	Parker et al.	128	898	
EXAMINER <u>H. P.</u>				DATE CONSIDERED <u>05/31/2001</u>			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.26	Application No. 09/748,412			
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Applicant Wouter E. Roorda				
				Filing Date December 21, 2000	Group Art Unit 3738			
FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
R	B1	EP 0665023	8/2/95	European				
	B2	EP 0970711	1/12/00	European				
	B3	WO 91/12846	9/5/91	PCT				
	B4	WO 95/24929	9/21/95	PCT				
	B5	WO 97/45105	12/4/97	PCT				
	B6	WO 99/63981	12/16/99	PCT				
	B7	WO 00/12147	3/9/00	PCT				
	B8	WO 00/64506	11/2/00	PCT				
	B9	WO 01/01890	1/11/01	PCT				
	B10	WO 01/45763	6/28/01	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
R	C1	Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2):252A (1989).						
R	C2	Komatsu et al., Neointimal Tissue Response at Sites of Coronary Stenting in Humans, Macroscopic, Histological, and Immunohistochemical Analyses, Circulation, 98:224-233 (1998).						
R	C3	Matsumaru et al., Embolic Materials for Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn. 8(7):555-569 (1997).						
R	C4	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6):2490-2498 (1985).						
R	C5	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol. 30(2):157-162 (1997).						
R	C6	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, Am. Heart J. 136(6):1081-1087 (1998).						
R	C7	Shigeno, Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor, Chem. Abstracts 125:212307 (1996).						
EXAMINER	<u>R</u>			DATE CONSIDERED		05/31/2004		
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								